Logo image of NYXH

NYXOAH SA (NYXH) Stock Fundamental Analysis

NASDAQ:NYXH - BE0974358906 - Common Stock

5.9 USD
-0.34 (-5.45%)
Last: 9/2/2025, 8:22:50 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NYXH. NYXH was compared to 190 industry peers in the Health Care Equipment & Supplies industry. NYXH may be in some trouble as it scores bad on both profitability and health. NYXH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NYXH had negative earnings in the past year.
In the past year NYXH has reported a negative cash flow from operations.
NYXH had negative earnings in each of the past 5 years.
NYXH had a negative operating cash flow in each of the past 5 years.
NYXH Yearly Net Income VS EBIT VS OCF VS FCFNYXH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

Looking at the Return On Assets, with a value of -66.28%, NYXH is doing worse than 73.16% of the companies in the same industry.
The Return On Equity of NYXH (-105.18%) is worse than 64.21% of its industry peers.
Industry RankSector Rank
ROA -66.28%
ROE -105.18%
ROIC N/A
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
NYXH Yearly ROA, ROE, ROICNYXH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

NYXH has a Gross Margin of 65.27%. This is in the better half of the industry: NYXH outperforms 69.47% of its industry peers.
NYXH's Gross Margin has been stable in the last couple of years.
NYXH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 65.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
NYXH Yearly Profit, Operating, Gross MarginsNYXH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

3

2. Health

2.1 Basic Checks

NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NYXH has more shares outstanding
The number of shares outstanding for NYXH has been increased compared to 5 years ago.
The debt/assets ratio for NYXH is higher compared to a year ago.
NYXH Yearly Shares OutstandingNYXH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
NYXH Yearly Total Debt VS Total AssetsNYXH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -2.04, we must say that NYXH is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.04, NYXH is doing worse than 61.05% of the companies in the same industry.
NYXH has a Debt/Equity ratio of 0.29. This is a healthy value indicating a solid balance between debt and equity.
NYXH has a Debt to Equity ratio of 0.29. This is comparable to the rest of the industry: NYXH outperforms 50.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Altman-Z -2.04
ROIC/WACCN/A
WACC7.43%
NYXH Yearly LT Debt VS Equity VS FCFNYXH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

NYXH has a Current Ratio of 2.63. This indicates that NYXH is financially healthy and has no problem in meeting its short term obligations.
NYXH has a Current ratio of 2.63. This is comparable to the rest of the industry: NYXH outperforms 53.16% of its industry peers.
A Quick Ratio of 2.38 indicates that NYXH has no problem at all paying its short term obligations.
NYXH's Quick ratio of 2.38 is in line compared to the rest of the industry. NYXH outperforms 58.42% of its industry peers.
Industry RankSector Rank
Current Ratio 2.63
Quick Ratio 2.38
NYXH Yearly Current Assets VS Current LiabilitesNYXH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

6

3. Growth

3.1 Past

NYXH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -41.57%.
Looking at the last year, NYXH shows a small growth in Revenue. The Revenue has grown by 2.94% in the last year.
NYXH shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 74.42% yearly.
EPS 1Y (TTM)-41.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.74%
Revenue 1Y (TTM)2.94%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%73.8%

3.2 Future

The Earnings Per Share is expected to grow by 2.97% on average over the next years.
The Revenue is expected to grow by 135.57% on average over the next years. This is a very strong growth
EPS Next Y-18.85%
EPS Next 2Y-6.18%
EPS Next 3Y2.97%
EPS Next 5YN/A
Revenue Next Year106.87%
Revenue Next 2Y166.9%
Revenue Next 3Y146.88%
Revenue Next 5Y135.57%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
NYXH Yearly Revenue VS EstimatesNYXH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
NYXH Yearly EPS VS EstimatesNYXH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NYXH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NYXH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYXH Price Earnings VS Forward Price EarningsNYXH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYXH Per share dataNYXH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.18%
EPS Next 3Y2.97%

More info and screens

0

5. Dividend

5.1 Amount

NYXH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NYXOAH SA

NASDAQ:NYXH (9/2/2025, 8:22:50 PM)

5.9

-0.34 (-5.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-18 2025-08-18/amc
Earnings (Next)11-13 2025-11-13
Inst Owners25.49%
Inst Owner Change-38.03%
Ins Owners22.07%
Ins Owner ChangeN/A
Market Cap220.84M
Analysts81.43
Price Target15.11 (156.1%)
Short Float %1.11%
Short Ratio2.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.5%
Min EPS beat(2)-22.16%
Max EPS beat(2)5.16%
EPS beat(4)2
Avg EPS beat(4)-4.61%
Min EPS beat(4)-22.16%
Max EPS beat(4)5.16%
EPS beat(8)6
Avg EPS beat(8)2.91%
EPS beat(12)7
Avg EPS beat(12)-7.28%
EPS beat(16)9
Avg EPS beat(16)-4.34%
Revenue beat(2)0
Avg Revenue beat(2)-19.91%
Min Revenue beat(2)-38.43%
Max Revenue beat(2)-1.4%
Revenue beat(4)0
Avg Revenue beat(4)-21.65%
Min Revenue beat(4)-38.43%
Max Revenue beat(4)-1.4%
Revenue beat(8)1
Avg Revenue beat(8)-22.06%
Revenue beat(12)1
Avg Revenue beat(12)-32.46%
Revenue beat(16)1
Avg Revenue beat(16)-37%
PT rev (1m)1.51%
PT rev (3m)2.55%
EPS NQ rev (1m)-6.44%
EPS NQ rev (3m)-25.09%
EPS NY rev (1m)-14.48%
EPS NY rev (3m)-14.48%
Revenue NQ rev (1m)-18.18%
Revenue NQ rev (3m)-73.36%
Revenue NY rev (1m)-20.91%
Revenue NY rev (3m)-42.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 38.44
P/FCF N/A
P/OCF N/A
P/B 2.58
P/tB 8.62
EV/EBITDA N/A
EPS(TTM)-2.45
EYN/A
EPS(NY)-2.37
Fwd EYN/A
FCF(TTM)-1.94
FCFYN/A
OCF(TTM)-1.89
OCFYN/A
SpS0.15
BVpS2.28
TBVpS0.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.28%
ROE -105.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 65.27%
FCFM N/A
ROA(3y)-31.19%
ROA(5y)-24.1%
ROE(3y)-40.78%
ROE(5y)-30.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.63%
GM growth 5YN/A
F-Score3
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.29
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 49.33%
Cap/Sales 29.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.63
Quick Ratio 2.38
Altman-Z -2.04
F-Score3
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)64.88%
Cap/Depr(5y)74.74%
Cap/Sales(3y)37.33%
Cap/Sales(5y)219.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-41.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.74%
EPS Next Y-18.85%
EPS Next 2Y-6.18%
EPS Next 3Y2.97%
EPS Next 5YN/A
Revenue 1Y (TTM)2.94%
Revenue growth 3Y74.42%
Revenue growth 5YN/A
Sales Q2Q%73.8%
Revenue Next Year106.87%
Revenue Next 2Y166.9%
Revenue Next 3Y146.88%
Revenue Next 5Y135.57%
EBIT growth 1Y-55.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.8%
EBIT Next 3Y1.88%
EBIT Next 5Y11.04%
FCF growth 1Y-45.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.67%
OCF growth 3YN/A
OCF growth 5YN/A